On July 23, 2026 — the same day the FDA advisory committee voted on peptide compounding — Eli Lilly quietly announced positive topline results from two more Phase 3 trials of retatrutide.

TRIUMPH-2 and TRIUMPH-3 are the fourth and fifth positive Phase 3 trials in retatrutide's development program. With these results, Lilly now has the clinical data package to support global regulatory submissions and plans to file a Biologics License Application (BLA) with the FDA in Q1 2027.

Here's what the data actually shows.

What Retatrutide Is

Retatrutide (LY3437943) is an investigational, once-weekly, triple hormone receptor agonist. It activates three receptors simultaneously:

GLP-1 receptor — appetite suppression, gastric emptying, insulin secretion
GIP receptor — additional satiety signaling, insulin sensitivity, fat metabolism
Glucagon receptor — direct energy expenditure and fat mobilization, thermogenesis

The glucagon component is what separates retatrutide from tirzepatide (dual GLP-1/GIP) and semaglutide (single GLP-1). Activating the glucagon receptor adds direct fat mobilization on top of appetite suppression — producing weight loss results that approach bariatric surgery outcomes in Phase 3 data.

Important: Retatrutide is an investigational molecule. It is not FDA approved. It cannot be legally sold or marketed for human use. BLA filing is planned for Q1 2027; approval, if granted, would follow regulatory review.

TRIUMPH-2 — Obesity with Type 2 Diabetes

Trial design: Phase 3, 80-week, randomized, double-blind, placebo-controlled. 1,152 participants with type 2 diabetes and obesity or overweight (average starting weight: 234.6 lbs, BMI 38.2).

Primary endpoint results at 80 weeks:

| Dose | Weight Change | Weight Lost | |---|---|---| | Retatrutide 4mg | -12.7% | -29.8 lbs | | Retatrutide 9mg | -19.1% | -45.4 lbs | | Retatrutide 12mg | -20.8% | -49.6 lbs | | Placebo | -4.0% | -9.3 lbs |

Glycemic control (key secondary endpoint):

A1C reduction at 80 weeks: up to -1.6% from a baseline of 7.7%
Clinically meaningful — a 1.5%+ A1C reduction is considered substantial in T2D management

Why this matters: T2D patients are the hardest obesity population to treat with GLP-1 agents — insulin resistance blunts the response and the disease itself complicates weight management. Achieving ~21% weight loss in this population is significant. The combination of weight loss and A1C reduction represents the cardiometabolic dual benefit this patient population most needs.

TRIUMPH-3 — Severe Obesity with Established Cardiovascular Disease

Trial design: Phase 3, 80-week, randomized, double-blind, placebo-controlled. 1,949 participants with severe obesity (BMI ≥35) and established cardiovascular disease, with or without T2D (average starting weight: 245.6 lbs, BMI 40.4).

Primary endpoint results at 80 weeks:

| Dose | Weight Change | Weight Lost | |---|---|---| | Retatrutide 9mg | -21.6% | -52.7 lbs | | Retatrutide 12mg | -22.6% | -55.8 lbs | | Placebo | -3.2% | -7.7 lbs |

Cardiovascular risk factor reductions (highest dose):

Triglycerides: -37.0%
Non-HDL cholesterol: -16.5%
Systolic blood pressure: -9.3 mmHg
Waist circumference: -7.5 in (19.0 cm)
hsCRP (high-sensitivity C-reactive protein): -51.2%

MACE analysis (cardiovascular events):

MACE-5 events (all-cause death, heart attack, stroke, heart failure, coronary revascularization): Hazard ratio 0.82 (95% CI: 0.55-1.22) — favors retatrutide but confidence interval crosses 1.0; not statistically conclusive
MACE-3 events (cardiovascular death, heart attack, stroke): Hazard ratio 1.12 (95% CI: 0.64-1.96) — numerically unfavorable but wide CI; not conclusive

Why this matters: TRIUMPH-3 is the first trial of retatrutide specifically in patients with established cardiovascular disease — the highest-risk obesity population. The weight loss results (22.6%) are extraordinary for this population. More notable: the cardiometabolic risk factor reductions are clinically meaningful across the board. A 51.2% reduction in hsCRP (a key inflammatory marker strongly associated with cardiovascular events) and a 37% triglyceride reduction in patients with existing CVD represent meaningful reductions in disease burden — independent of the weight loss itself.

The MACE data is inconclusive — the trial was not powered to detect cardiovascular outcome benefits, and the event rates were lower than anticipated in both arms. A dedicated cardiovascular outcomes trial (CVOT) would be required to establish cardiovascular benefit, similar to SELECT (semaglutide) and SURPASS-CVOT (tirzepatide).

The Complete TRIUMPH Program — Five Phase 3 Wins

With TRIUMPH-2 and TRIUMPH-3, Lilly now has five positive Phase 3 trials:

TRIUMPH-1 — Obesity without T2D: ~28% mean weight loss at 80 weeks (previously reported)
TRIUMPH-2 — Obesity + T2D: up to 20.8% at 80 weeks ✅ new
TRIUMPH-3 — Severe obesity + established CVD: up to 22.6% at 80 weeks ✅ new
Obstructive sleep apnea + obesity — positive results (previously reported)
Knee osteoarthritis — positive results (previously reported)

This is an unusually broad Phase 3 program — five indications, all positive. Most obesity drugs are approved for a single indication. Retatrutide's multi-indication data package is part of why Lilly describes it as a potential "important future tool in the management of cardiometabolic health" rather than simply a weight loss drug.

What the Safety Data Shows

TRIUMPH-2 most common adverse events (retatrutide vs. placebo):

Diarrhea: 27-34% vs. 13%
Nausea: 14-28% vs. 8%
Constipation: 14-17% vs. 9%
Decreased appetite: 6-17% vs. 5%
Vomiting: 6-16% vs. 4%

TRIUMPH-3 most common adverse events:

Diarrhea: 24-30% vs. 9%
Nausea: 22% vs. 6%
Constipation: 16-18% vs. 7%
Decreased appetite: 14% vs. 3%
Hyperglycemia: 3-4% vs. 13% (placebo had significantly more — consistent with better glycemic control on retatrutide)

Discontinuation rates were meaningfully higher on retatrutide than placebo in both trials — 8-14% vs. 5% — primarily driven by GI adverse events. These are consistent with the class effect seen across GLP-1 therapies.

Dysesthesia (a sensory side effect unique to retatrutide, not seen with other GLP-1s) occurred in 6-7% of participants across trials — a pattern that warrants continued monitoring in larger real-world populations.

The Regulatory Timeline

Q1 2027: Lilly plans to submit a Biologics License Application (BLA) to the FDA for retatrutide. The BLA will include the full clinical data package from the TRIUMPH program.

Post-BLA review: Standard FDA review timelines run 10-12 months for Priority Review designations. If retatrutide receives Priority Review (likely given the cardiovascular population data), FDA action could come by late 2027 or early 2028.

Global submissions: Lilly indicated plans to support global submissions with this data package — EU, UK, and other major markets expected to follow a similar timeline to US.

What This Means for the Current Landscape

The obesity drug pipeline has never been more active. In 2026 alone:

Foundayo (orforglipron) — FDA approved April 2026 (oral GLP-1, daily pill)
Wegovy HD (semaglutide 7.2mg) — FDA approved December 2025
CagriSema NDA filed — Novo Nordisk (GLP-1 + amylin combination)
Retatrutide BLA — Q1 2027

By 2028, patients may have access to single GLP-1s, dual agonists, triple agonists, amylin combinations, oral formulations, and monthly dosing options. The question shifts from "which drug is available" to "which drug is right for this patient's specific cardiometabolic profile."

That question requires tracking. Knowing which compound produced which outcome — in your body, at your dose, alongside your other biomarkers — is what makes protocol optimization possible instead of guesswork.

The Bottom Line

TRIUMPH-2 and TRIUMPH-3 confirm what TRIUMPH-1 suggested: retatrutide delivers weight loss outcomes in the 20-23% range across multiple high-risk populations, with meaningful improvements in cardiometabolic risk factors beyond just the scale.

The 51.2% hsCRP reduction and 37% triglyceride reduction in patients with established cardiovascular disease are the data points that elevate this beyond a weight loss conversation into a cardiovascular risk management conversation.

BLA filing Q1 2027. FDA approval, if granted, likely 2027-2028.

The landscape is evolving faster than any point in obesity medicine history.

→ Track your protocol as it does at PeptidesGPT.com/research

Sources:

Eli Lilly press release: "Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials" — July 23, 2026 (PR Newswire)
ClinicalTrials.gov: TRIUMPH-2 (NCT05929079), TRIUMPH-3 (NCT05882045)
Lilly Cardiometabolic Health: Kenneth Custer, Ph.D., executive vice president and president

PeptidesGPT is an educational platform. Retatrutide is an investigational compound not approved by the FDA. This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before making decisions about your health or protocol.